Opendata, web and dolomites

HD4HF

Heart Damper: a revolutionary device for Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HD4HF project word cloud

Explore the words cloud of the HD4HF project. It provides you a very rough idea of what is the project "HD4HF" about.

rejection    billion    actual    alone    quick    patient    transapical    longer    cure    community    treat    heart    healthcare    time    economic    health    ease    65    once    invasive    feasibility    systolic    solution    fitted    tah    give    worldwide    innovative    total    contractile    public    treatments    15    transplantation    viability    expectancy    energy    epidemic    left    million    assist    ventricular    penetration    symptoms    cacapacity    segment    independently    38    therapies    staggering    stably    rare    procedure    upwards    age    designed    12    implanted    innovation    eucardia    sources    sufficient    external    cardiac    artificial    owned    market    impossible    respect    people    supports    stage    productivity    protected    2030    inevitably    damper    patients    minimally    pharmacological    80    intended    risk    moves    implantable    life    instrument    individual    countries    reducing    family    device    issue    apart    patent    vad    household    introduction    hd    residual    sme    ventricle    surgical    quality    hf    granted    social   

Project "HD4HF" data sheet

The following table provides information about the project.

Coordinator
EUCARDIA SRL 

Organization address
address: VIA GIACOMO LEOPARDI 7
city: MILANO
postcode: 20123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUCARDIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

This project supports the market introduction of the Heart Damper (HD), a very innovative implantable cardiac device, intended to provide a simple, quick and cost-effective solution to treat patients affected by systolic heart failure.

Heart Failure (HF) is a growing epidemic and a major public health issue: only in EU and US it affects today about 15 million people, with an expected growth of about 38% by 2030. 2 million of these patients are affected by advanced heart failure: a phase in which the pharmacological therapies alone are no longer sufficient to manage the symptoms. Late stage treatments, such as Ventricular Assist Device (VAD) or Total Artificial Heart (TAH) are indeed inevitably associated with high risk of rejection and low quality of life. HF has no actual cure apart from heart transplantation, which is very rare and impossible for people over 65 (80% of HF patients). In addition, HF has a significant social cost, as it doesn’t affect only the individual patient, but also his family and his community. In the US, for example, the costs related to the loss of work and household productivity are estimated at $ 8.2 billion/year (by 2030, $12.3 billion/year).

The Heart Damper, a minimally invasive cardiac device, will make it possible to give patients a longer and better life expectancy, independently from their age, at the same time reducing the staggering associated healthcare costs. Designed to be stably fitted into the left ventricle by a simple transapical surgical procedure, once implanted it moves upwards exploiting the residual contractile cacapacity of the heart, without any need of external energy sources. The device is protected by a patent fully owned by Eucardia, which has been granted in Europe, US and other major countries worldwide.

The SME 1 Instrument will enable Eucardia to assess in detail the technical feasibility and economic viability of its innovation, in order to ease HD market penetration, in respect of HF market segment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HD4HF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HD4HF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More